First proposed panels on acute leukemia for four-color immunophenotyping by flow cytometry from the Brazilian group of flow cytometry-GBCFLUX

Ikoma, Maura R. V.; Sandes, Alex Freire; Thiago, Leandro S.; Cavalcanti, Geraldo Barroso; Lorand-Metze, Irene; Costa, Elaine Sobral da; Pimenta, Glicínia; Santos-Silva, Maria Cláudia; Bacal, Nydia Strachman; Yamamoto, Masahiro; Souto, Elizabeth Xisto

doi:10.1002/cyto.b.21175

Cited by 10 publications

(14 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further refine and confirm the gating of blasts, CD34 was used. 11,16,20 In this study, B-ALL and T-ALL expressed CD34 in 85.4% and 24.1% respectively.…”

Section: Funding Sourcesupporting

confidence: 50%

“…Lineage specific cytoplasmic CD3 is constantly expressed at high levels in T-ALL, which made the gating of blasts easier. 1,16 The interpretation of cytoplasmic CD3 should be coupled with surface CD3 for the reason that most of the T-ALL cases express cCD3 with negative smCD3. 16 All 29 cases of T-ALL expressed cCD3 and none expressed CD79a.…”

Section: Methodsmentioning

confidence: 99%

“…The use of these markers in combination is more pertinent than that of individual markers, for they provide a unique immunophenotype enabling the identification of the cell population in question. 9,11,16,17 The antibody panel for the limited flow cytometry were lineage-specific B-cell and T-cell markers which include cytoplasmic CD79a and cytoplasmic CD3, respectively. Cellular maturity was assessed by the presence or absence of the following markers: CD45, CD34, cytoplasmic TdT, CD10 and CD19.…”

Section: Funding Sourcementioning

confidence: 99%

See 2 more Smart Citations

Cost-Effectiveness of Limited Screening Panel for Acute Lymphoblastic Leukemia Diagnosis in a Resource-Limited Setting

Medalla¹,

Gepte²,

Pido³

et al. 2021

PJP

View full text Add to dashboard Cite

Background. Flow cytometry is an invaluable tool in the diagnostic evaluation of acute leukemia and post therapy monitoring; however, majority of Filipino population cannot afford the cost. The use of a minimal screening panel which is both cost-effective and provides an accurate diagnosis of acute lymphoblastic leukemia is seen as an alternative.Objectives. We aim to determine the cost-effectiveness and accuracy of using a minimal screening panel for the diagnosis of acute lymphoblastic leukemia (ALL).Methodology. We selected a limited panel of 9 antibodies comprising of CD45/CD19/CD20/CD10/HLA-DR/ CD34/cCD3/cCD79a/cTdt and retrospectively reviewed newly diagnosed cases of B-cell and T-cell ALL from September 2016 to December 2019 using this panel. Results. Out of 719 bone marrow aspirates submitted for basic leukemia flow cytometric analysis we identified 268 ALL cases (239 B-ALL and 29 T-ALL).In all cases, a diagnosis was established using the limited panel. Compared to the current cost of our comprehensive panel (₱ 9,903.60). This limited panel cost ₱ 3,062.29, that offers a 69.08% savings per test, which translated to a ₱1.2 million savings a year (for an average of 180 annual cases). Conclusion.We underscore the utility of a limited panel for the diagnosis of ALL. Although this panel remains to be assessed with a larger validation cohort, its application in resource-limited developing countries is diagnostically useful and cost-effective.Recommendation. The use of a limited panel of 9 antibodies is recommended as a screening panel for patients who are highly suspected of having ALL both clinically and initial bone marrow smear assessment.

show abstract

“…To further refine and confirm the gating of blasts, CD34 was used. 11,16,20 In this study, B-ALL and T-ALL expressed CD34 in 85.4% and 24.1% respectively.…”

Section: Funding Sourcesupporting

confidence: 50%

Section: Methodsmentioning

confidence: 99%

Section: Funding Sourcementioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness of Limited Screening Panel for Acute Lymphoblastic Leukemia Diagnosis in a Resource-Limited Setting

Medalla¹,

Gepte²,

Pido³

et al. 2021

PJP

View full text Add to dashboard Cite

show abstract

“…Recently, GBCFLUX published diagnostic panels for acute leukemia recommended to most Brazilian MFC laboratories. 31 …”

Section: Methodsmentioning

confidence: 99%

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia

Ikoma

Beltrame

Ferreira

et al. 2015

Revista Brasileira de Hematologia e Hemoterapia

Self Cite

View full text Add to dashboard Cite

Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute lymphoblastic leukemia are multiparametric flow cytometry and polymerase chain reaction. Both provide similar results at a minimal residual disease level of 0.01% of normal cells, that is, detection of one leukemic cell in up to 10,000 normal nucleated cells. Currently, therapeutic protocols establish the minimal residual disease threshold value at the most informative time points according to the appropriate methodology employed. The expertise of the laboratory in a cancer center or a cooperative group could be the most important factor in determining which method should be used. In Brazil, multiparametric flow cytometry laboratories are available in most leukemia treatment centers, but multiparametric flow cytometry processes must be standardized for minimal residual disease investigations in order to offer reliable and reproducible results that ensure quality in the clinical application of the method. The Minimal Residual Disease Working Group of the Brazilian Society of Bone Marrow Transplantation (SBTMO) was created with that aim. This paper presents recommendations for the detection of minimal residual disease in acute lymphoblastic leukemia based on the literature and expertise of the laboratories who participated in this consensus, including pre-analytical and analytical methods. This paper also recommends that both multiparametric flow cytometry and polymerase chain reaction are complementary methods, and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene assays are necessary in Brazil.

show abstract

“…Dear Editor, We have read with great interest the outstanding paper of Ikoma et al (1) that designed antibodies panels with four-color combinations to be applied in the diagnosis of acute leukemia, by flow cytometry, in Brazil. Considering that most laboratories in that country employ flow cytometers equipped with three or four fluorescence channels and, moreover, that the use of broad panels, as recommended by Euroflow (2), is not an easy task to these and other laboratories working in developing countries; this study is an important first step to validate an uniform panel to acute leukemia analysis in this landscape.…”

mentioning

confidence: 99%

Brazilian group of flow cytometry (GBCFLUX) panels for acute leukemia: Some insights

Matos¹

2015

Cytometry

View full text Add to dashboard Cite

First proposed panels on acute leukemia for four-color immunophenotyping by flow cytometry from the Brazilian group of flow cytometry-GBCFLUX

Cited by 10 publications

References 57 publications

Cost-Effectiveness of Limited Screening Panel for Acute Lymphoblastic Leukemia Diagnosis in a Resource-Limited Setting

Cost-Effectiveness of Limited Screening Panel for Acute Lymphoblastic Leukemia Diagnosis in a Resource-Limited Setting

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia

Brazilian group of flow cytometry (GBCFLUX) panels for acute leukemia: Some insights

Contact Info

Product

Resources

About